Specific human antibodies for selective cancer therapy
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 7, 2006
Grant Date -
Apr 15, 2004
app pub date -
Dec 31, 2001
filing date -
Dec 29, 2000
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention is directed to novel peptides and polypeptides that specifically bind to target cells and may have anti-cancer activity, especially blood-related cancers. The present invention includes a peptide or polypeptide comprising an Fv molecule, having a heavy variable chain comprising CDR3, CDR2 and CDR1 regions comprising the amino acid sequences SEQ ID NOS:8, 115 and 114, respectively.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully